U.S. Markets close in 3 hrs 32 mins

Entera Bio Ltd. (ENTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.0700-0.0600 (-1.45%)
As of 12:21PM EDT. Market open.

Entera Bio Ltd.

Kiryat Hadassah Minrav Building
Fifth Floor Kiryat Hadassah PO Box 12117
Jerusalem 9122002
972 2 532 7151

Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Dr. Hillel GalitzerChief Operating Officer359kN/A1978
Dr. Phillip Schwartz Ph.D.Exec. VP, Pres of R&D and Director441kN/A1962
Dr. Arthur C. Santora II, M.D., Ph.D.Chief Medical Officer355kN/A1951
Dr. Spiros JamasCEO & DirectorN/AN/A1961
Ms. Dana Yaacov-Garbeli CPAChief Financial OfficerN/AN/A1989
Dr. Roger J. GarceauChief Devel. Advisor & DirectorN/AN/A1954
Mr. Ramesh RatanU.S. Chief Financial OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Corporate Governance

Entera Bio Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.